Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy
Authors:
- 5 April 2013
- journal article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 251 (9) , 2099-2110
Abstract
To clarify the efficacy of combined therapy with intravitreal ranibizumab injections and photodynamic therapy (PDT) in patients with symptomatic polypoidal choroidal vasculopathy (PCV). We retrospectively reviewed 57 treatment-naïve eyes of 57 patients. Thirty-two patients were treated with standard fluence PDT (PDT group), and 25 patients were treated with three consecutive monthly intravitreal injections of ranibizumab and standard fluence PDT (ranibizumab plus PDT group). All patients were followed for at least 24 months. In the ranibizumab plus PDT group, the mean best-corrected visual acuity (BCVA) levels of decimal (logMAR equivalent) significantly improved from 0.30 (0.52) at baseline to 0.55 (0.26) at 24 months (P < 0.001). In the PDT group, the BCVA levels stabilized from 0.26 (0.58) at baseline to 0.25 (0.60) at 24 months. The mean changes in the BCVA in the ranibizumab plus PDT group and the PDT group were improvement of 2.63 lines and decline of 0.16 lines respectively (P = 0.010). The mean number of PDTs at 24 months in the ranibizumab plus PDT group and the PDT group were 1.4 and 2.6 respectively. Increased subretinal hemorrhages were seen in eight (18.0 %) eyes, all of which were belonging to the PDT group. Combined intravitreal ranibizumab and PDT was significantly more effective in maintaining and improving VA for PCV patients compared with PDT monotherapy over 24 months.Keywords
This publication has 39 references indexed in Scilit:
- INTRAVITREAL RANIBIZUMAB COMBINED WITH VERTEPORFIN PHOTODYNAMIC THERAPY FOR TREATING POLYPOIDAL CHOROIDAL VASCULOPATHYRetina, 2011
- Subfoveal Retinal and Choroidal Thickness After Verteporfin Photodynamic Therapy for Polypoidal Choroidal VasculopathyAmerican Journal of Ophthalmology, 2011
- PHOTODYNAMIC THERAPY, RANIBIZUMAB, AND RANIBIZUMAB WITH PHOTODYNAMIC THERAPY FOR THE TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHYRetina, 2011
- PHOTODYNAMIC THERAPY WITH VERTEPORFIN IN POLYPOIDAL CHOROIDAL VASCULOPATHYRetina, 2010
- Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary studyBritish Journal of Ophthalmology, 2010
- Combined Photodynamic Therapy With Verteporfin and Intravitreal Bevacizumab for Polypoidal Choroidal VasculopathyAmerican Journal of Ophthalmology, 2010
- Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachmentBritish Journal of Ophthalmology, 2008
- Correlation between Focal Macular Electroretinograms and Angiographic Findings after Photodynamic TherapyInvestigative Ophthalmology & Visual Science, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Polypoidal choroidal vasculopathy: natural historyAmerican Journal of Ophthalmology, 2002